
Opinion|Videos|January 31, 2025
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Retina World Congress 2026: Identifying real-world durability gaps in wet AMD treatment
2
Retina World Congress 2026: Rethinking macular hole surgery without gas tamponade
3
Retina World Congress 2026: Can vibration reduce pain during intravitreal injections?
4
Retina World Congress 2026: Diagnosing macular telangiectasia in a field of mimickers
5






















